Wedmont Private Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Wedmont Private Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,762	Closed	-$357K	–	956
2026 Q1	$357K	Sell	8,762 -3,121	-26%	-$67.3K	0.01%	609
2025 Q4	$315K	Buy	11,883 +468	+4%	+$11K	0.01%	631
2025 Q3	$288K	Buy	+11,415	New	+$266K	0.01%	622

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wedmont Private Capital's APLS Position: Q2 2026 in Review

Wedmont Private Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 8,762 shares — an estimated $357K sold.

Wedmont Private Capital first reported a position in APLS in Q3 2025 and held it in 3 quarters. The position peaked at $357K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Wedmont Private Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Wedmont Private Capital sold 8,762 Apellis Pharmaceuticals shares in Q2 2026, an estimated $357K.
Wedmont Private Capital first reported a position in Apellis Pharmaceuticals in Q3 2025 and held it in 3 quarters.
Wedmont Private Capital's Apellis Pharmaceuticals position peaked at $357K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Wedmont Private Capital's 13F filing for Q2 2026, filed 13 Jul 2026.